# 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa

> **NCT00456794** · PHASE2 · COMPLETED · sponsor: **Kyowa Kirin, Inc.** · enrollment: 325 (—)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Istradefylline (KW-6002)

## Key facts

- **NCT ID:** NCT00456794
- **Lead sponsor:** Kyowa Kirin, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** 325 (—)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00456794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00456794, "12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00456794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*